Plaque Stability and Metabolomics in Coronary Heart Disease

The Relationship Between Plaque Stability Evaluated by IVUS and Metabolomics in Stable Coronary Heart Disease Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05270330

Enrollment

100

Registered

2022-03-08

Start date

2021-07-01

Completion date

2024-07-31

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

plaque stability, metabonomics

Brief summary

At present, the investigators don't know the relationship between plaque stability and the metabonomics changes. In the present study, investigators will evaluate the plaque stability by intravascular unltrasound in stable coronary heart patients, and metabonomics was also assessed by high throughput sequencing. Statistic analysis were carried out to analyze the correlation between plaque stability and metabonomics changes among these study patients.

Interventions

OTHERThis is an observational study, we don't have any interventions.

No intervention

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Patients who diagnosed with stable coronary heart disease and evaluated for plaque stability by IVUS will be recruited.

Exclusion criteria

* renal insufficiency with serum creatinine \> 20 mg/L; * regnant/lactating women, or the women receive hormone replacement therapy in premenopausal or postmenopausal; * patients have a history of abusing alcohol or other drugs in the past two years, active hepatitis, cirrhosis; * endocrine abnormalities without therapy (diabetic ketoacidosis, thyroid disease, etc.); * The body's inflammatory disease, rheumatoid arthritis, osteoarthritis, ulcerative bowel disease, systemic lupus erythematosus (sle), etc.), myositis/myopathy, cancer; * Dilated cardiomyopathy, valvular heart disease, persistent atrial fibrillation; * patients recently injured;（8）Other researchers don't agree to join this study.

Design outcomes

Primary

Measure	Time frame	Description
Plaque stability	07/01/2021-07/31/2024	The investigators will use the intravascular ultrasound to assess the coronary plaque stability of the patients with coronary heart disease.

Secondary

Measure	Time frame	Description
Metabonomics	07/01/2021-07/31/2024	Serum or plasma will be collected by the investigators and high-throughput sequencing will be used to assess the metabonomics of patients with coronary heart disease.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026